WO1998017302A1 - Total synthesis of the amino hip analogue of didemnin a - Google Patents
Total synthesis of the amino hip analogue of didemnin a Download PDFInfo
- Publication number
- WO1998017302A1 WO1998017302A1 PCT/US1997/019211 US9719211W WO9817302A1 WO 1998017302 A1 WO1998017302 A1 WO 1998017302A1 US 9719211 W US9719211 W US 9719211W WO 9817302 A1 WO9817302 A1 WO 9817302A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- didemnin
- mmol
- added
- cbz
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Didemnins were isolated from the Caribbean tunicate Trididemnum solidum. ' These cyclic depsipeptides possess a variety of biological activities including in vitro and in vivo antiviral, antilumor, and immunosuppressive activities.2-5 They are potent inhibitors of L1210 leukemia cells in vitro, and are also active in vivo against P388 leukemia and D 16 melanoma.3 Didemnin B, a more active compound of this class, is approximately twenty times more cytotoxic than didemnin A in vitro and has undergone phase II clinical trials for antituinor activity.- Both didemnins A and B exhibit antiviral activity against DNA and RNA viruses, with didemnin B being more active * The structures of didemnins A and B have been established as 1 and 2, respectively. ⁇
- didemnin B binds to a site on Nb2 node lymphoma cells and that this binding may be responsible for the immunosuppressive activity.
- Schreiber and co-workers 1 ⁇ have reported that didemnin A binds elongation factor-l ⁇ (EF-l ⁇ ) in a GTP-dependent manner wliich suggests EF- l ⁇ may be the target responsible for the ability of didemnins to inhibit protein synthesis.
- Tripeptide 5 Preparation of the diprotected tripeptide unit is shown in Scheme II. Our approach began with methylation of the uncommon amino acid, Cbz-D-lcucine, 7, with CH3l/NaH. l 1 Coupling of the derivative Cbz-D-MeLeuOH with the hydroxyl group of the threonine derivative L-TlirOEt 1 ⁇ was accomplished with dicyclohexylcarbodiimide (DCC) ' 3 to provide the dipeptide 8. Ester hydrolysis with potassium hydroxide afforded the desired carboxylic acid wl ⁇ ch was then protected as a phenacyl (Pac) ester 9. Coupling with the tyrosine derivative BocMe2TyrOH ⁇ 4 followed by removal of the Boc protecting group ⁇ afforded 10. Removal of the phenacyl function ⁇ provided the key fragment 5.
- DCC dicyclohexylcarbodiimide
- Reagents a) (i) CH3I, NaH, THF; (ii) L-T rOEt, DCC, CH CI 2; b) (i) KOH, MeOH; (ii) plienacylBr, Et3N, EtO ⁇ c; c) BocMe 2 TyrOH, DCC. DM ⁇ P, CH 2 C1 2 ; d) Zn, HO ⁇ c/H 2 0.
- Tetrapeptidc 6 The construction of fragment 6 involves two novel subunits (25,45)-aminoisovalerylpropionic acid (Aip) and (35, 4R, 55)-isostatine (1st). The synthesis of the required isostatine derivative involves (2R, 35)- ⁇ //o-isoleucine. The expensive
- (2R, 35)- ⁇ //o-isoleucine can be obtained from commercially available (25, 35)-isoleucine, 11, by conversion to the hydroxy acid with retention and its conversion in two steps to the amino acid with inversion (Scheme III).
- ' 8 Conversion of (25, 35)-isoleucine to the corresponding ⁇ - hydroxy acid 12 was accomplished by using a well-known procedure ⁇ that allows overall retention of configuration via a double inversion. Esterification was carried out with acetyl chloride in methanol, and the corresponding ⁇ -hydroxy methyl ester was transformed into the tosyloxy methyl ester 13.
- Treatment of the tosylate with sodium azide in D F provided the ⁇ - azido ester 14 stereoselectively. Saponification of the ester afforded the ⁇ -azido acid 15.
- the next step toward the synthesis of the tripeptide fragment (6) involved formation of the amino Hip subunit.
- This unit was synthesized from Cbz-L-valine, 21, utilizing a procedure based in part on the work of Nagarajan.21
- EHMM ethyl hydrogen methyl malonate
- Sodium borohydride reduction of the ⁇ -keto ester produced a diastereomeric mixture of alcohols which were separable by column chromatography.
- Reagents a) (i) CO(imiti) 2 , THF; (ii) EHMM, iPrMgBr; l>) (i) NaBH , ElOII; (ii) KOH, MeOH; (iii) LeuOMe, DCC, CH 2 CI 2 ; c) (i) KOH, MeOH; (ii) phenacytBr. Et 3 N. EtO ⁇ c; (iii) PCC, ⁇ I ⁇ 3, CH 2 Cl 2 ; cl) (i) Zn/HO ⁇ c; (ii) ProOTMSe, DCC. CH 2 Cl 2 ; (iii) H , Pd/C, MeOH; (iv) BocIslOH lfi, DCC, CH 2 CI 2 ; (v) HCI. dioxane.
- Reagents a) (i)EDC, NMM. DMF; (ii) TB ⁇ F. THF; (iii) TFA, THF; b) EDC, DMF.
- Electron impact (El) mass spectra were recorded on a Finnigan MAT CH-5 DF spectrometer.
- High resolution (HRFAB) and fast atom bombardment (FAB) mass spectra were recorded on a VG ZAB-SE mass spectrometer operating in the FAB mode using magic bullet matrix. 2 ⁇ Microanalytical results were obtained from the School of Chemical Sciences Microanalytical Laboratory.
- Infrared (IR) spectra were obtained on an IR/32 FTIR spectrophotometer. Solid samples were analyzed as chloroform solutions in sodium chloride cells. Liquids or oils were analyzed as neat films between sodium chloride plates.
- Optical rotations (in degrees) were measured with a DIP 360 or a DIP 370 digital polarimeter with an Na lamp (589 nm) using a 5- X 0.35-cm (1.0 mL) cell. Melting points were determined on a capillary melting point apparatus and are not corrected. Nonnal phase column t chromatography was performed using Merck-kieselgel silica gel (70 - 230 mesh). Fuji-Davison C 18 gel (100 - 200 mesh) was used for reversed phase column chromatography. All solvents were spectral grade. Analytical thin layer chromatography was performed on precoated plates (Merck, F-254 indicator).
- THF was distilled from sodium benzophenone ketyl and CH2CI2 from P2O5.
- Dimethylformamide (DMF), triethylamine (E13N), and TV-methylmorpholine (NMM) were distilled from calcium hydride and stored over KOH pellets.
- Pyridine was distilled from KOH and stored over molecular sieves. Other solvents used in reactions were reagent grade without purification.
- the solution was then evaporated to dryness and the oily residue partitioned between ether (30 mL) and water (60 mL).
- the ether layer was washed with aqueous sodium bicarbonate (5 mL) and the combined aqueous layers were acidified with 4N IIC1 to pH 3.
- the solution was extracted with ethyl acetate (3 X 15 mL) and the extract washed with 5% aqueous sodium thiosulfate (2 X 10 mL) and water ( 10 mL).
- the solution was dried over sodium sulfate and the solvent evaporated to give an oily residue which crystallized overnight.
- L-Threonine Ethyl Ester (L-ThrOEt).
- a current of dry HC1 was passed through a suspension of L-threonine (35.0 g, 0.29 mol) in absolute ethanol (350 mL), with shaking, until a clear solution formed.
- the solution then refluxed for 30 min, and was evaporated to dryness under reduced pressure, and the oily residue was taken up in absolute ethanol (175 mL) and, again, taken to dryness under reduced pressure.
- the oily residue was then treated with a saturated solution of ammonia in chloroform.
- the ammonium chloride was filtered off and the filtrate was taken to dryness at O'C under reduced pressure.
- Z-D-Methylleucylthreonine Ethyl Ester (8).
- Z-D-MeLeuOH (2.12 g, 7.59 mmol) was dissolved in 100 mL of CH2CI2 and cooled to O'C.
- DCC (1.72 g, 8.35 mmol) was added and the solution was stirred at O'C for 10 min.
- L-ThrOEt (1.12 g, 7.59 m ol) in 5 mL of CH2CI2 was added and the solution was allowed to warm to rt. After approximately 15 h, dicyclohcxylurea was removed by filtration and washed with CH2CI2.
- Z-D-Methylleucylthreonine Z-D-MeLcuThrOH.
- Z-D-MeLeuThrOEt 1.80 g, 4.42 mmol was dissolved in methanol and 2N KOH was slowly added to the mixture at O'C. The solution was stirred for 2 h. TLC analysis (CHCl3 MeOH 95:5) showed the reaction to be complete. The mixture was neutralized using 2N HC1. The solvent was then evaporated. The solution was partitioned between ethyl acetate and water and the organic layer separated. Aqueous HC1 was added to the aqueous layer to pH 3.
- Z-D-Methylleucylthreonine Phenacyl Ester (9).
- Z-D-MeLeuThrOH (1.50 g, 3.95 mmol) was dissolved in ethyl acetate (25 L).
- Triethylamine (0.39 g, 3.95 mmol) and phenacyl bromide (0.79 g, 3.98 mmol) were added and, within a few minutes, a precipitate formed. The mixture was stirred overnight. At this time, water and ether were added and the two layers separated. The organic layer was washed with 0.1N HO, saturated sodium bicarbonate, and brine, and then dried over MgS04.
- the deep orange gel was diluted with 30 mL of water and washed with pentane (2 X 30 mL).
- the aqueous phase was acidified with solid citric acid (pH 2).
- Ethyl acetate was used for extraction.
- the combined extracts were washed with brine, dried (MgS ⁇ 4) and concentrated in vacuo.
- Methyl (25, 3S)-2-IIydroxy-3-methylpentanoate Acetyl chloride (6.13 mL) was added dropwise to MeOH (90 mL) cooled in an ice bath. After addition was complete, a solution of the ⁇ -hydroxy acid (23.0 g, 0.17 mol) in MeOH (60 mL) was added. The solution was stirred at O'C for 1 h, then at rt overnight, concentrated and diluted with ether.
- Cbz-DihydroAipOH Cbz-DihydroAipOEt (5.99 g, 17.7 mmol) was dissolved in methanol and 2N KOH was slowly added to the mixture at 0 "C. The solution was allowed to stir for 2 h. TLC analysis (hexane/ethyl acetate 10: 1) showed the reaction to be complete. At this time, 2N HCl was added to neutralization. The solvent was evaporated and the solution was partitioned between ethyl acetate and water. The organic layer was separated. Aqueous IIC1 was added to bring the aqueous layer to pH 3 which was then extracted with ethyl acetate.
- Cbz-Aip-Leu-Pro-OTMSe Cbz-Aip-Leu-Pro-OTMSe.
- Cbz-Aip-Leu-OH (35.7 mg, 85.0 ⁇ mol) was dissolved in dry CH2CI2 (1.0 mL) and the solution was cooled to O'C.
- DCC (26.1 mg, 0.13 mmol) was added and the mixture was stirred for 30 min at O'C.
- Pro-OTMSe (18.5 mg, 85.0 ⁇ mol) in CH2CI2 ( 1.0 mL) was added and the solution was stirred for 30 min at 0 "C and at rt overnight. The residue was concentrated and taken up in ethyl acetate.
- Boc-Ist- ⁇ ip-Lcu-Pro-OTMSe Boc-Ist-OH (7.51 mg, 27.3 ⁇ mol) was dissolved in dry CH2CI2 ( 1.0 mL) and the solution was cooled to O'C. DCC (10.52 mg, 0.089 mmol) was added and the mixture was stirred for 30 min at O'C. H-Aip-Leu-Pro-OTMSe (3.28 mg, 27.3 ⁇ mol) in CII2CI2 (1.0 mL) was added and the solution was stirred for 30 min at O'C and at rt overnight. The residue was concentrated and taken up in ethyl acetate.
- the solution was then concentrated to 0.50 mL, kept at 0 'C for 24 h, then diluted with ether.
- the organic layer was washed with 10% HCl, 5% NaHC ⁇ 3, and saturated NaCl solutions.
- the organic layer was dried (Na2S ⁇ 4), filtered, and concentrated.
- the crude oil was purified by reversed phase HPLC using a gradient system of CH3CN/H2O to give 1.41 mg (40%) of the protected analogue; FABMS 1076.7 (M + H). see Supplementary Material, S-8; HRFABMS Calcd for C57H86N7O13 (M + H) 1076.6284, Found 1076.6283.
- the compound (1.41 mg) was dissolved in isopropyl alcohol (0.50 mL) and 10% Pd C catalyst (0.50 mg) was added. The solution was hydrogenated for 3 h. At this time, the catalyst was rerrioved by filtration over celite and the solvent removed to afford the desired compound.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Catalysts (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP51964998A JP2001504814A (en) | 1996-10-24 | 1997-10-24 | Total Synthesis of Amino Hip Analogs of Didemnin A |
EP97946294A EP0956033B1 (en) | 1996-10-24 | 1997-10-24 | Total synthesis of the amino hip analogue of didemnin a |
US09/284,905 US6380156B1 (en) | 1996-10-24 | 1997-10-24 | Total synthesis of the amino hip analogue of didemnin A |
DK97946294T DK0956033T3 (en) | 1996-10-24 | 1997-10-24 | Total synthesis of the amino-Hip analog of didemnin A |
AU51495/98A AU726146B2 (en) | 1996-10-24 | 1997-10-24 | Total synthesis of the amino hip analogue of didemnin A |
DE69723728T DE69723728T2 (en) | 1996-10-24 | 1997-10-24 | TOTAL SYNTHESIS OF THE AMINO HIP ANALOG OF DIDEMNIN A |
CA002269878A CA2269878A1 (en) | 1996-10-24 | 1997-10-24 | Total synthesis of the amino hip analogue of didemnin a |
AT97946294T ATE245435T1 (en) | 1996-10-24 | 1997-10-24 | TOTAL SYNTHESIS OF THE AMINO HIP ANALOG BY DIDEMNIN A |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2910996P | 1996-10-24 | 1996-10-24 | |
US60/029,109 | 1996-10-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998017302A1 true WO1998017302A1 (en) | 1998-04-30 |
WO1998017302A9 WO1998017302A9 (en) | 1998-10-15 |
Family
ID=21847275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/019211 WO1998017302A1 (en) | 1996-10-24 | 1997-10-24 | Total synthesis of the amino hip analogue of didemnin a |
Country Status (11)
Country | Link |
---|---|
US (1) | US6380156B1 (en) |
EP (1) | EP0956033B1 (en) |
JP (1) | JP2001504814A (en) |
AT (1) | ATE245435T1 (en) |
AU (1) | AU726146B2 (en) |
CA (1) | CA2269878A1 (en) |
DE (1) | DE69723728T2 (en) |
DK (1) | DK0956033T3 (en) |
ES (1) | ES2202644T3 (en) |
PT (1) | PT956033E (en) |
WO (1) | WO1998017302A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002596A2 (en) * | 2000-06-30 | 2002-01-10 | Pharma Mar, S.A. | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them |
US7064105B2 (en) | 2000-04-07 | 2006-06-20 | The Trustees Of The University Of Pennsylvania | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them |
US7348311B2 (en) | 1989-09-29 | 2008-03-25 | Pharma Mar, S.A. | Derivatives of dehydrodidemnin B |
US7381703B2 (en) | 2003-03-12 | 2008-06-03 | Dana-Faber Cancer Institute, Inc. | Aplidine for multiple myeloma treatment |
US7507766B2 (en) | 2000-10-12 | 2009-03-24 | Pharma Mar, S.A. | Treatment of cancers |
US7576188B2 (en) | 2003-03-12 | 2009-08-18 | Pharma Mar, S.A.U. | Antitumoral treatments |
US7651997B2 (en) | 2000-04-07 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them |
US8030279B2 (en) | 2003-03-21 | 2011-10-04 | The Trustees Of The University Of Pennsylvania | Tamandarin analogs and fragments thereof and methods of making and using |
US8258098B2 (en) | 2006-02-28 | 2012-09-04 | Pharma Mar, S.A. | Antitumoral treatments |
US8420130B1 (en) | 1998-02-18 | 2013-04-16 | Pharma Mar S.A. | Pharmaceutical formulation of a didemnin compound |
CN101575363B (en) * | 2000-06-30 | 2016-01-27 | 法马马有限公司 | The synthetic method of Aplidine and new antitumoral derivatives and preparation and application thereof |
US10538535B2 (en) | 2017-04-27 | 2020-01-21 | Pharma Mar, S.A. | Antitumoral compounds |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004051025A1 (en) * | 2004-10-20 | 2006-04-27 | Bayer Healthcare Ag | Substituted nonadepsipeptides |
DE102004051024A1 (en) * | 2004-10-20 | 2006-04-27 | Bayer Healthcare Ag | Heterocyclyl-substituted nonadepsipeptides |
DE102004051023A1 (en) * | 2004-10-20 | 2006-05-04 | Bayer Healthcare Ag | Deoxo-nonadepsipeptides |
DE102004053410A1 (en) * | 2004-11-05 | 2006-05-11 | Bayer Healthcare Ag | Cyclic nonadepsipeptidamides |
DE102006003443A1 (en) * | 2006-01-25 | 2007-07-26 | Aicuris Gmbh & Co. Kg | New lysobactin derivatives useful for treating bacterial infections in humans and animals |
DE102006018250A1 (en) * | 2006-04-13 | 2007-10-18 | Aicuris Gmbh & Co. Kg | Process for preparing cyclic depsipeptides |
DE102006018080A1 (en) * | 2006-04-13 | 2007-10-18 | Aicuris Gmbh & Co. Kg | Lysobactinamide |
JP7568510B2 (en) * | 2018-11-30 | 2024-10-16 | 中外製薬株式会社 | Method for deprotecting peptide compounds or amide compounds, method for removing resin in solid-phase reaction, and method for producing peptide compounds |
-
1997
- 1997-10-24 DE DE69723728T patent/DE69723728T2/en not_active Expired - Fee Related
- 1997-10-24 US US09/284,905 patent/US6380156B1/en not_active Expired - Fee Related
- 1997-10-24 AT AT97946294T patent/ATE245435T1/en not_active IP Right Cessation
- 1997-10-24 DK DK97946294T patent/DK0956033T3/en active
- 1997-10-24 JP JP51964998A patent/JP2001504814A/en not_active Ceased
- 1997-10-24 CA CA002269878A patent/CA2269878A1/en not_active Abandoned
- 1997-10-24 PT PT97946294T patent/PT956033E/en unknown
- 1997-10-24 AU AU51495/98A patent/AU726146B2/en not_active Ceased
- 1997-10-24 EP EP97946294A patent/EP0956033B1/en not_active Expired - Lifetime
- 1997-10-24 WO PCT/US1997/019211 patent/WO1998017302A1/en active IP Right Grant
- 1997-10-24 ES ES97946294T patent/ES2202644T3/en not_active Expired - Lifetime
Non-Patent Citations (2)
Title |
---|
J. AM. CHEM. SOC., 1989, Vol. 111, HAMADA Y. et al., "Efficient Total Synthesis of Didemnins A and B", pages 669-673. * |
TETRAHEDRON, 1988, Vol. 44, No. 12, HARRIS B.D. et al., "Synthetic Studies of Didemnins. III. Syntheses of Statine and Isostatine Stereoisomers", pages 3489-3500. * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7348311B2 (en) | 1989-09-29 | 2008-03-25 | Pharma Mar, S.A. | Derivatives of dehydrodidemnin B |
US8420130B1 (en) | 1998-02-18 | 2013-04-16 | Pharma Mar S.A. | Pharmaceutical formulation of a didemnin compound |
US7651997B2 (en) | 2000-04-07 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them |
US7737114B2 (en) | 2000-04-07 | 2010-06-15 | The Trustees Of The University Of Pennsylvania | Didemnin analogs and fragments and methods of making and using them |
US7064105B2 (en) | 2000-04-07 | 2006-06-20 | The Trustees Of The University Of Pennsylvania | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them |
US7122519B2 (en) | 2000-04-07 | 2006-10-17 | The Trustees Of The University Of Pennsylvania | Didemnin analogs and fragments and methods of making and using them |
US7678765B2 (en) | 2000-06-30 | 2010-03-16 | Pharma Mar, S.A. | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them |
CN101575363B (en) * | 2000-06-30 | 2016-01-27 | 法马马有限公司 | The synthetic method of Aplidine and new antitumoral derivatives and preparation and application thereof |
KR100866056B1 (en) * | 2000-06-30 | 2008-10-30 | 파르마 마르, 에스.에이. | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them |
CN104650177A (en) * | 2000-06-30 | 2015-05-27 | 法马马有限公司 | Synthetic Methods For Aplidine And New Antitumoral Derivatives, Methods Of Making And Using Them |
CZ304204B6 (en) * | 2000-06-30 | 2014-01-02 | Pharma Mar, S. A. | Aplidine derivatives |
US7348310B2 (en) | 2000-06-30 | 2008-03-25 | Pharma Mar, S.A. | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them |
WO2002002596A2 (en) * | 2000-06-30 | 2002-01-10 | Pharma Mar, S.A. | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them |
JP2004502702A (en) * | 2000-06-30 | 2004-01-29 | ファルマ・マール・ソシエダード・アノニマ | Methods for synthesizing aplidine and novel antitumor derivatives, methods for producing and using them. |
WO2002002596A3 (en) * | 2000-06-30 | 2002-05-23 | Pharma Mar Sa | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them |
US7507766B2 (en) | 2000-10-12 | 2009-03-24 | Pharma Mar, S.A. | Treatment of cancers |
US7576188B2 (en) | 2003-03-12 | 2009-08-18 | Pharma Mar, S.A.U. | Antitumoral treatments |
US7381703B2 (en) | 2003-03-12 | 2008-06-03 | Dana-Faber Cancer Institute, Inc. | Aplidine for multiple myeloma treatment |
US8030279B2 (en) | 2003-03-21 | 2011-10-04 | The Trustees Of The University Of Pennsylvania | Tamandarin analogs and fragments thereof and methods of making and using |
US8258098B2 (en) | 2006-02-28 | 2012-09-04 | Pharma Mar, S.A. | Antitumoral treatments |
US10538535B2 (en) | 2017-04-27 | 2020-01-21 | Pharma Mar, S.A. | Antitumoral compounds |
US11332480B2 (en) | 2017-04-27 | 2022-05-17 | Pharma Mar, S.A. | Antitumoral compounds |
US11339180B2 (en) | 2017-04-27 | 2022-05-24 | Pharma Mar, S.A. | Antitumoral compounds |
US11713325B2 (en) | 2017-04-27 | 2023-08-01 | Pharma Mar, S.A. | Antitumoral compounds |
Also Published As
Publication number | Publication date |
---|---|
PT956033E (en) | 2003-10-31 |
DK0956033T3 (en) | 2003-10-06 |
AU5149598A (en) | 1998-05-15 |
DE69723728D1 (en) | 2003-08-28 |
DE69723728T2 (en) | 2004-06-03 |
EP0956033B1 (en) | 2003-07-23 |
EP0956033A4 (en) | 2000-06-21 |
US6380156B1 (en) | 2002-04-30 |
EP0956033A1 (en) | 1999-11-17 |
AU726146B2 (en) | 2000-11-02 |
ES2202644T3 (en) | 2004-04-01 |
JP2001504814A (en) | 2001-04-10 |
ATE245435T1 (en) | 2003-08-15 |
CA2269878A1 (en) | 1998-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6380156B1 (en) | Total synthesis of the amino hip analogue of didemnin A | |
WO1998017302A9 (en) | Total synthesis of the amino hip analogue of didemnin a | |
JP3579750B2 (en) | Human cancer inhibitory pentapeptide methyl esters | |
JP3579752B2 (en) | Human cancer inhibitory peptide amides | |
Miyazaki et al. | Synthesis and antitumor activity of novel dolastatin 10 analogs | |
US5554725A (en) | Synthesis of dolastatin 15 | |
US5294603A (en) | Pharmaceutical compositions containing didemnins | |
JP3579751B2 (en) | Human cancer-inhibiting pentapeptide amides and esters | |
JP4477777B2 (en) | New cyclosporine | |
Mayer et al. | Synthesis of new didemnin B analogs for investigations of structure/biological activity relationships | |
Rich et al. | Synthesis and antimitogenic activities of four analogs of cyclosporin A modified in the 1-position | |
DE3885959T2 (en) | Cyclosporins. | |
WO1996014856A1 (en) | Cancer inhibitory peptides | |
JPH04211699A (en) | Novel immunosuppressive cyclosporine analogue having denatured amino acid at position-8 | |
US4997648A (en) | Peptides and medical use thereof | |
US6034058A (en) | Semi-synthetic alanyl dilemnin analogs | |
EP0973518B1 (en) | Semi-synthetic studies toward didemnin analogues | |
US5633346A (en) | Process for systhesizing cyclic peptides | |
Scherkenbeck et al. | A highly efficient synthesis of the anthelmintic cyclooctadepsipeptide PF1022A | |
Mattern et al. | Synthetic studies of microcolin B | |
US20010007855A1 (en) | Semi-synthetic studies toward didemnin analogues | |
Li | Total syntheses of didemnins A, B, C, and detoxin D (1) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1-26, DESCRIPTION, REPLACED BY NEW PAGES 1-27; PAGES 27-29, CLAIMS, REPLACED BY NEW PAGES 28 AND 29; PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 519649 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 1998 519649 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2269878 Country of ref document: CA Ref country code: CA Ref document number: 2269878 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 51495/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997946294 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09284905 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997946294 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 51495/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997946294 Country of ref document: EP |